# reload+after+2024-01-20 19:46:09.044899
address1§9713 Key West Avenue
address2§Suite 400
city§Rockville
state§MD
zip§20850
country§United States
phone§301 944 1700
website§https://maxcyte.com
industry§Medical Devices
sector§Healthcare
longBusinessSummary§MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
fullTimeEmployees§125
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Maher  Masoud', 'age': 47, 'title': 'President, CEO, Head of Global Business Development & Legal Officer, Secretary & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 612065, 'exercisedValue': 0, 'unexercisedValue': 436890}, {'maxAge': 1, 'name': 'Dr. Cenk  Sumen Ph.D.', 'age': 49, 'title': 'Chief Scientific Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 575600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas J. Swirsky CFA, CPA', 'age': 54, 'title': 'Chief Financial Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ronald Evan Holtz CPA, Ph.D.', 'age': 65, 'title': 'Executive Vice President of Administration', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 649385, 'exercisedValue': 0, 'unexercisedValue': 6397638}, {'maxAge': 1, 'name': 'Mr. Sean  Menarguez', 'title': 'Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas Michael Ross', 'age': 62, 'title': 'Executive Vice President of Global Sales & Marketing', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jack  Horgan', 'title': 'Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. J. Stark Thompson Ph.D.', 'age': 81, 'title': 'Consultant', 'yearBorn': 1942, 'fiscalYear': 2022, 'totalPay': 84708, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James  Brady Ph.D.', 'title': 'Senior VP of Technical Applications & Customer Support', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sarah Haecker Meeks Ph.D.', 'title': 'Senior Vice President of Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§1
boardRisk§8
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.003
priceToSalesTrailing12Months§12.522658
currency§USD
dateShortInterest§1702598400
forwardEps§-0.44
exchange§NMS
quoteType§EQUITY
shortName§MaxCyte, Inc.
longName§MaxCyte, Inc.
firstTradeDateEpochUtc§1627651800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§99edb1ce-9d5d-37b7-967d-699d6c90ba1a
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§7.0
targetMeanPrice§9.75
targetMedianPrice§10.5
recommendationMean§1.4
recommendationKey§strong_buy
numberOfAnalystOpinions§4
quickRatio§11.917
grossMargins§0.87606
ebitdaMargins§-1.12925
trailingPegRatio§None
